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Clinical use of cyclin-dependent kinase 
(CDK) 4/6 inhibitors in patients with 
breast cancer — literature review
ABSTRACT
Luminal subtype predominates in patients diagnosed with breast cancer — the incidence in developed countries 
is up to 80% of all cases. Hormonal therapy is an important part of the treatment; this is used as adjuvant treat-
ment after radical surgery, and is also the preferred option of palliative systemic treatment. Unfortunately, during 
adjuvant hormonal treatment as well as palliative therapy, primary or secondary resistance may appear. To prevent 
and overcome these phenomena a strategy of combined pharmacological treatment was developed. In many 
clinical trials the effectiveness of doublets composed of hormonal and molecularly targeted drugs was assessed. 
So far, combination of hormonal therapy with cyclin-dependent kinase 4 and 6 inhibitors appears to be the most 
successful. Such a combination used in the first or further lines of palliative treatment prolongs progression-free 
survival. Moreover, its toxicity is relatively low and manageable. Until now, three drugs have been approved for 
treatment of breast cancer: palbociclib, ribociclib, and abemaciclib. This review describes the mechanism of ac-
tion of cyclin-dependent kinase 4 and 6 inhibitors and summarises the most relevant trials, which have become 
the basis of these drugs’ approval.
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Introduction
Breast cancer is a heterogeneous disease, which 
includes tumours of different biology and different clini-
cal course, drug sensitivity, and prognosis. According to 
molecular classification based on gene expression analy-
sis, hormone receptors (HRs), HER2 and Ki67 — four 
subtypes of breast cancer were identified based on im-
munohistochemistry: luminal A, luminal B, HER2-de-
pendent, and triple negative. It is estimated that in west-
ern countries tumours expressing hormonal receptors 
account for about 80% of cases of breast cancer [1]. An 
indispensable element of systemic treatment of patients 
with such cancers is hormone therapy. It is used for both 
radical and palliative treatment. It is the first-choice 
treatment for patients with advanced HER2-negative 
breast cancer, except when the disease is extremely 
dynamic and is associated with the risk of critical organ 
failure. Adjuvant hormone therapy in breast cancer pa-
tients includes: tamoxifen (selective estrogen receptor 
modulators — SERMs), luteinising-hormone-releasing 
hormone (LHRH) analogues, aromatase inhibitors 
(AIs), steroid (exemestane), as well as non-steroidal aro-
matase inhibitors (anastrozole, letrozole). In addition, 
fulvestrant (selective ER down-regulator — SERD), 
megestrol acetate, and medroxyprogesterone are also 
used in metastatic disease. AIs and fulvestrant can be 
used only in patients with hormonally inactive ovaries, 
either by natural or artificially induced menopause [2, 3]. 
A significant problem associated with hormonal 
therapy is drug resistance emerging at various time 
points. Based on the results of Early Breast Cancer 
Trialists’ Collaborative Group meta-analysis [4], approx. 
15% of patients experience disease recurrence during 
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five years of adjuvant hormone therapy with tamoxifen. 
However, relapses are also observed many years after 
treatment cessation: after 10 years the relapse rate 
increases to 25%, and after 15 years to 33%. Approx. 
50–70% of patients with metastatic breast cancer have 
clinical benefit from the first-line of hormonal therapy, 
and the remaining patients experience primary resist-
ance to hormone therapy [5]. In general, all patients 
treated with palliative treatment develop resistance, 
and the duration of response is reduced along the next 
hormonal therapy lines. Primary hormonal resistance 
is defined as relapse within the first two years of adju-
vant hormonal therapy or disease progression within 
six months since introduction of palliative hormonal 
treatment. Secondary hormone-resistance is defined in 
case of recurrence diagnosed during adjuvant hormonal 
therapy, but more than two years after it starts or after 
its completion, or progression occurs during palliative 
treatment, six months after its introduction [6]. 
In order to prevent the development of resistance to 
hormonal therapy, attempts have been made to combine 
hormone therapy with molecularly targeted therapies:
 — mammalian target of rapamycin (mTOR) kinase 
inhibitors: everolimus with exemestane [5], temsiroli-
mus with letrozole [7], everolimus with tamoxifen [8];
 — anti-HER2 drugs: trastuzumab with AIs [9–11], 
lapatinib with letrozole [12], lapatinib with fulves-
trant [13];
 — phosphoinositide 3-kinase (PI3K) inhibitors: pic-
tilisib with fulvestrant [14], buparlisib with fulves-
trant [15];
 — 26S proteasome inhibitor: bortezomib with fulves-
trant [16]; 
 — histone deacetylase inhibitor: entinostat with 
exemestane [17].
However, most of the aforementioned trials failed, 
and these drugs (except everolimus) did not enter clini-
cal practice.
The greatest success so far has been the combination 
of hormones with cyclin-dependent kinase (CDK) 4/6 in-
hibitors. Such therapy not only significantly prolongs 
progression-free survival (PFS) compared to hormone 
therapy alone, but is also associated with relatively low 
toxicity. This is a review of the literature on the use of 
CDK 4 and 6 inhibitors — palbociclib, ribociclib, and 
abemaciclib — in breast cancer patients, with a special 
focus on the activity of these drugs in patients with ad-
vanced HR-positive/HER2-negative disease.
Mechanism of action of CDK 
4/6 inhibitors
Cancer cells are characterised by loss of prolifera-
tion and aging control, resulting from dysfunction of 
so-called cell cycle checkpoints. One of them is G1 phase 
checkpoint in which, after checking for the potential 
presence of DNA damage, the cell enters the division 
phase or is stopped in resting phase G0. Passing through 
this point and cell cycle progression also depend on the 
presence of favourable metabolic conditions and many 
signals promoting and inhibiting cellular growth, also 
extracellular. After crossing this checkpoint, the cell 
continues the division cycle regardless of the presence 
of growth factors, so it is also called the restriction 
point [18]. The direct regulator of G1 phase checkpoint, 
which incorporates the aforementioned signals, is the 
mechanism in which retinoblastoma protein (RB) plays 
a central role. Non-phosphorylated RB protein inhibits 
cell cycle progression. On the other hand, its phospho-
rylation by the complex the complex of cyclin-dependent 
kinases 4 and 6 (CKD4 and CDK6) and cyclin D al-
lows the cycle to pass to the next phase [19, 20]. This is 
a target for CKD 4 and 6 inhibitors, which prevent the 
phosphorylation of RB protein and cell cycle progres-
sion. This mechanism is shown in Figure 1. Preclinical 
studies have shown that short-term inhibition of CDK 
4 and 6 kinases causes a temporary stop of the cell cycle 
at G1 phase checkpoint, followed by a cell cycle progres-
sion. In the case of long-term inhibition of CDK 4 and 
6, cell cycle inhibition is maintained, followed by apop-
tosis or aging of the cell [21]. Studies on the inhibition 
of cyclin-dependent kinase activity in neoplastic cells 
have been initiated from compounds being non-selective 
inhibitors of these enzymes, such as alvociclib (CDK1, 
CDK2, CDK4, CDK6, CDK7, and CDK9 inhibitor) or 
seliciclib (CDK1, CDK2, CDK7, and CDK9 inhibitor) 
[19]. Unfortunately, the activity of these substances on 
tumour cells is limited, with high toxicity, especially my-
elotoxicity.
A breakthrough in these studies was the develop-
ment of selective CDK 4 and 6 inhibitors. Among them 
three compounds have shown particularly promising 
properties and have been successfully moved into 
the next phases of clinical trials. Palbociclib (Ibrance, 
PD-0332991; Pfizer), ribociclib (LEE011; Novartis), 
and abemaciclib (LY2835219; Eli Lilly & Company) 
are potent, selective inhibitors of CDK 4 and 6 and do 
not inhibit other cyclin-dependent kinases at all or to 
a very small extent (palbociclib inhibits CDK1 activity 
1000 times less, abemaciclib — at least 160 times less, 
and ribociclib — more than 1000 times less). These 
drugs are competitive inhibitors — they compete with 
ATP molecules for binding to the active site of kinases 
[20]. Importantly, these medicines are given orally. 
Palbociclib and ribociclib have a very similar chemi-
cal structure, abemaciclib is different in structure and 
there are reports that it has a greater ability to cross 
the blood-brain barrier than the other two inhibitors, 
particularly palbociclib [22]. 
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Figure 1A. Factors determining the passing 
of a cell cycle through the checkpoints; B. Cell 
cycle progression through the checkpoint in 
case of inactive 4/6: complex of serine/thre-
onine-protein kinase consisting of cyclin-de-
pendent kinase 4 and 6 and their activating 
subunits — cyclins D1, D2, and D3 phosphoryl-
ates RB protein and related proteins P107 and 
130. This prevents sequestration of transcrip-
tion factors from E2F family, which results in 
the expression of genes responsible for cell 
cycle progression. Cell cycle progress through 
this mechanism is promoted by multiple sig-
nalling pathways and growth factors (NF-kB, 
PI3K/mTOR, MAPKs, STATs, Wnt/b-catenin, 
ER/PgR); C. Cell cycle arrest at checkpoint after 
cyclin-dependent kinases inhibition: RB protein 
in hypophosphorylation state binds transcrip-
tional factors from E2F family and prevents 
the expression of genes involved in cell cycle 
transition from G1 to S phase. Intracellular 
natural non-specific cyclin-dependent kinase 
inhibitors are proteins from Cip-Kip family, 
while proteins from INK4 family specifically in-
hibit CDK4 and 6. CDK 4/6 — cyclin-dependent 
kinases 4/6; mTOR — mammalian target of 
rapamycin kinase; NF-kB — nuclear factor 
kappa-light-chain-enhancer of activated B cells; 
MAPKs — mitogen-activated protein kinases; 
STATs — signal transducers and activators 
of transcription; ER — oestrogen receptor; 
PgR — progesterone receptor; Wnt — signal 
glycoprotein; PI3K — phosphoinositide 3-kinase
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As with other cytostatics, the antitumor properties 
of CDK inhibitors can be strengthened by combination 
with drugs from other groups. Of note, by inhibiting cell 
cycle in G1 phase, CDK 4 and 6 inhibitors may exhibit 
antagonistic properties to drugs targeting synthesis phase 
or mitosis, and even to ionising radiation [23, 24]. The 
solution to this problem could be administration of ad-
ditional medicines at fixed points in time to synchronise 
the cell cycle and to sensitise different cell populations 
to their action [20, 24]. In theory, inhibitors of CDKs 
4 and 6 may antagonise the effects of immune checkpoint 
inhibitors because activated T lymphocytes require the 
efficient functioning of cyclin-dependent kinases.
Dean et al. investigated the inhibition effect of CDK 
4 and 6 activity on cell lines undergoing gamma-irradiation 
[24]. Significant shift of DNA double strand break repair 
from homologous recombination mechanism (providing 
repair relatively error-free) was observed toward the 
mechanism of non-homologous end joining (NHEJ). This 
mechanism is fraught with more errors, which can cause 
genomic instability and generate or accelerate carcinogen-
esis. Hence careful planning should be undertaken to as-
sess the association of CDK inhibitors with chemotherapy, 
particularly in the context of radical treatment. 
These concerns seem not to apply to the combination 
of CDK 4 and 6 inhibitors with hormone drugs. First of 
all, theoretically the effects of estrogens as stimulators 
for cell growth and proliferation are driven by a cyclin 
D-dependent mechanism, cyclin-dependent kinase, 
and RB protein. Secondly, cell and animal models 
have shown a strong association between oestrogen 
and stimulation of this mechanism: activated estrogen 
receptors (ERs) as transcription factors increase expres-
sion of cyclin D, and in ER+ breast cancer cells CDK 
4 and 6 are strongly activated through these receptors 
and other signalling pathways involved in oncogenesis 
[20]. In addition, permanently increased cyclin D1 activ-
ity and RB phosphorylation are likely to be associated 
with the development of hormonal resistance of breast 
cancer cells [25]. CDK 4 and 6 inhibitors exhibit activity 
in RB protein-expressing cells, and it was revealed that 
this characterises over 90% of ER+ breast cancers [26]. 
In breast cancer patients there was also an increase in 
the activity of the remaining proteins involved in the 
mechanism based on the RB protein. Amplification of 
CCND1 gene encoding cyclin D1 was reported in 38% 
of patients with breast cancer with HER2 hyperexpres-
sion, 58% of patients with luminal B breast cancer, and 
29% of patients with luminal A breast cancer; however, 
increasing the number of copies of CDK4 — in 24%, 
25%, and 14% of patients, respectively [27].
The theoretical assumption that CDK 4 and 6 inhibi-
tors should exhibit anti-tumour effects on ER-positive 
breast cancer cells and synergism with hormone therapy 
have been confirmed in studies on cell lines [28], animal 
models [29, 30], and in phase 1 clinical trials [28, 29]. 
Their positive results have become the starting point for 
further phase clinical studies. 
Palbociclib — pivotal studies
Palbociclib is a pyridopyrimidine derivative. The 
drug also exhibits activity against HER2-positive breast 
cancer cells, especially when accompanied by ER expres-
sion [28]. The half-life of the drug is about 26 hours, the 
recommended daily dose is 125 mg, given in a 3/1 sche-
dule (the drug is taken daily for three weeks, followed 
by a one week break). At this dosage, nadir neutrophil 
and platelet counts are usually observed during the 
week when the drug is not taken, with an increase in the 
number of blood cells thereafter [20]. Haematological 
adverse reactions are most commonly seen, but others 
include fatigue, diarrhoea, nausea, and constipation, 
which usually are not severe.
The efficacy of palbociclib used in monotherapy in 
patients with advanced breast cancer was assessed in 
a phase 2 clinical study published by DeMichele et al. 
[31]. The study included 37 breast cancer patients with 
immunohistochemically confirmed expression of RB 
protein. In 31 patients the receptor profile was ER+/ 
/HER2–, in two — ER+/HER2+, and in four — ER–/ 
/HER2–. In total, 24 patients had at least two lines of 
previous hormone therapy, and 28 had at least two lines 
of chemotherapy. The primary endpoints were direct 
response and treatment tolerance, secondary endpoints 
included PFS and assessment of potential predictive 
biomarkers (RB expression/localisation, Ki67 expression, 
protein loss, and CCND1 amplification). Clinical benefit 
[partial response (PR) and stable disease (SD) for at least 
6 months] were reported in 19% of all patients and median 
PFS was 3.7 months. These results were numerically better 
in patients with ER expression and in those who received 
prior hormone therapy. Unfortunately, the predictive 
value of biomarkers was not demonstrated. The results 
of the study confirmed the efficacy of the drug in patients 
with advanced breast cancer and once again highlighted 
the group of patients with ER expression as specific be-
neficiaries of this therapy. Palbociclib monotherapy in this 
group of patients made it possible to achieve PFS similar 
to the hormone therapy results of consecutive lines.
Studies on efficacy of palbociclib combined with 
hormone therapy in subsequent palliative treatment 
lines had acronym PALOMA (Palbociclib: Ongoing 
Trials in the Management of Breast Cancer).
PALOMA-1 study
The PALOMA-1/TRIO-18 phase 2 study included 
postmenopausal patients with ER+/HER2– receptor 
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profile, who had not received prior palliative systemic 
treatment [32]. Patients were consecutively assigned to 
two cohorts: recruitment to the first cohort was based 
only on the mentioned receptor profile, allocation to 
the second cohort as well as ER+/HER2– feature, 
required the presence of amplification of the cyclin 
D1 coding gene (CCND1), loss of the P16 protein 
gene (INK4A/CDKN2A), or both. Patients from both 
cohorts were assigned to two study arms: they received 
either letrozole (standard dosage) or letrozole in 
combination with palbociclib (dosage as above). The 
primary endpoint of the study was PFS as assessed by 
the investigator. Recruitment to cohort 2 was stopped 
after unplanned interim analysis of the results in co-
hort 1, which showed a significantly higher efficacy 
of combination therapy. Investigators concluded that 
further recruitment of patients based on molecular 
criteria would not improve the screening of patients 
compared to ER/HER2 assessment alone. A combined 
PFS analysis in both cohorts was also allowed. In total 
165 patients were included in the study. After approx. 
28–29 months of follow-up, median PFS was 10.2 and 
20.2 months for patients treated with letrozole and both 
drugs, respectively (HR 0.488, 95% CI 0.319–0.748, 
p = 0.0004). In cohort 1, including 66 patients, median 
PFS was 5.7 and 26.1 months, respectively (HR 0.299; 
95% CI 0.156–0.572; p < 0.0001), and in cohort 2, invol-
ving 99 patients, it was 11.1 and 18.1 months, respectively 
(HR 0.508; 95% CI 0.303–0.853; p = 0.0046).
Based on these findings, the US Food and Drug 
Administration (FDA) in February 2015 granted ac-
celerated approval for palbociclib in this indication. In 
March 2017, the drug was registered in the standard 
procedure in combination with aromatase inhibitor in 
the first-line palliative treatment of postmenopausal 
patients with HRs+/HER2– breast cancer.
This was possible by confirmation of the impres-
sive results of the PALOMA-1 study in the PALO-
MA-2 phase 3 trial for patients previously not systemati-
cally treated for advanced disease. 
PALOMA-2 study
The inclusion criteria in the PALOMA-2 study were 
as in cohort 1 of the PALOMA-1 study discussed above. 
Patients were similarly assigned in a 2:1 ratio to two 
arms — experimental (palbociclib and letrozole) and 
standard treatment (letrozole) [33]. The study protocol 
did not allow crossover. The primary endpoint was PFS 
assessed by the investigator, and secondary endpoints 
included overall survival (OS), overall response rate 
(ORR), clinical benefit rate (CBR), patient reported 
outcome, pharmacokinetics, and safety. The study in-
volved 666 patients. Almost half of them had metastases 
to the parenchymal organs, 37% of patients had newly 
diagnosed metastatic breast cancer, 63% of patients 
received prior systemic treatment as part of radical 
treatment: almost half of all patients had chemotherapy, 
and 56% had hormone therapy (including 46% with ta-
moxifen and 21% with NSAI). Median PFS was 24.8 and 
14.5 months, respectively (HR 0.58, 95% CI 0.46–0.72, 
p <0.001). Subgroup analysis showed greater efficacy 
of combination therapy regardless of age (< 65 years 
vs. ≥ 65 years), race (white vs. Asian), metastases location 
(visceral vs. other), previous adjuvant hormone therapy 
or chemotherapy, the type of the last hormone drug 
(AI vs. anti-estrogen) or histological subtype (ductal 
vs. lobular carcinoma) — confirming the results of the 
PALOMA-1 study [34]. The quality of life (QoL) of 
patients included in the study was assessed based on 
FACT-B (Functional Assessment of Cancer Therapy 
— Breast) questionnaire, which included a general as-
sessment of QoL (FACT-General, FACT-G) and breast 
cancer-related QoL (Breast Cancer-Specific Subscale 
— BCS). The questionnaire evaluated five aspects of 
patient welfare: physical, social, emotional, functional, 
and disease related (BCS). No statistically significant 
differences were found in the QoL of patients treated 
with palbociclib and letrozole compared to hormone 
therapy alone. The authors conclude that combination 
therapy as well as standard first-line hormone therapy 
can help maintain health-related QoL (HRQOL) [35].
In both studies, at the time of publication of the 
above-mentioned articles, no overall survival results 
were achieved. Such data from the PALOMA-1/TRIO-
18 study were presented at this year’s Annual ASCO 
Meeting (2017). By December 2016, 116 deaths had 
been reported. Median OS was 37.5 and 34.5 months, re-
spectively, and the difference in mortality was not signifi-
cant [HR = 0.897 (95% CI 0.623–1.24), p = 0.281] [36]. 
No differences were found when analysing separately the 
survival of patients in both study cohorts. These disap-
pointing data the authors tried to explain, among others, 
by the fact that the phase 2 study was not adequately 
designed to assess OS, slightly more patients treated 
with standard therapy received further antineoplastic 
treatment (86 vs. 79%), and more received at least three 
palliative treatment lines (37% vs. 18%). On the other 
hand, less than 3% of patients were treated with CDK 
4 and 6 inhibitor beyond progression. Hence, the results 
of the PALOMA-2 study regarding OS are even more 
impatiently awaited, albeit with slightly less optimism.
PALOMA-3 study
The clinical value of palbociclib was also assessed in 
patients previously treated with palliative hormone ther-
apy. This was a goal of the phase 3 PALOMA-3 study, 
which compared the combination of palbociclib (stand-
ard dosage) and fulvestrant (500 mg, standard dosage) 
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with fulvestrant monotherapy in randomly assigned (2:1) 
patients [37, 38]. The study involved 521 patients with 
advanced HRs+/HER2– breast cancer, who had previ-
ously received hormone therapy: 40% of patients had 
AI, 14% tamoxifen, and 46% had both. 33% of patients 
received palliative chemotherapy. 37% of patients re-
ceived at least two lines of any pharmacological palliative 
treatment. Importantly, 21% of patients included in the 
study were premenopausal — they underwent pharma-
cological suppression of ovarian function. The median 
follow-up time was over 15 months. Combination thera-
py was more effective with respect to PFS, which was the 
primary endpoint. Median PFS was 11.2 and 4.6 months, 
respectively (HR 0.50, 95% CI 0.40–0.62, p < 0.0001). 
The secondary endpoints of the study were, among oth-
ers, overall survival, ORR, patient-reported outcomes, 
pharmacokinetics, treatment safety, and biomarker 
evaluation of tumour tissue [PIK3CA gene mutations, 
quantitative assessment of estrogen and progesterone 
receptor (PgR) expression] [38]. At the time of publi-
cation of the first results of the study, mature data on 
OS was not yet available, but the study protocol did 
not permit crossover, which allows us to expect reliable 
data. Patient-reported outcomes included a HRQoL 
assessment as measured by the EQ-5D questionnaire 
(EuroQol Group 5-Dimension Self-Report Question-
naire), QLQ-C30 [European Organisation for Research 
and Treatment of Cancer (EORTC) Quality of Life 
Core Module], and QLQ-BR23 (EORTC Breast Cancer 
Module). Combination therapy has enabled patients 
to maintain overall QoL, while in patients treated with 
fulvestrant and placebo it was significantly impaired 
(p = 0.03). Experimental treatment also enabled pa-
tients to improve emotional function as compared to 
placebo (p = 0.002) [37]. Unfortunately, it was not 
possible to identify biomarkers with predictive value 
for experimental treatment. PIK3CA gene mutations 
in circulating tumour DNA were detected in 33% out 
of 395 patients included in the study. No association 
between PIK3CA gene status and efficacy was found. No 
association was also found for level of hormone receptor 
expression or for the type of hormone therapy used or 
for the response to it [38].
Adverse events during palbociclib 
treatment
The most commonly observed grade 3/4 adverse 
events in the above-mentioned studies were haemato-
logical disorders. Neutropaenia was reported in 54% of 
patients treated with palbociclib and letrozole [32] and 
65% of patients treated with palbociclib and fulvestrant 
[37]. For comparison, after the hormonal treatment 
alone, the figure was 1%.
Leukopaenia was reported in 19% and 28% of 
patients treated with the above-mentioned combina-
tion therapies, respectively. Despite such frequent 
neutropaenia, patients treated with palbociclib rarely 
experienced febrile neutropaenia — no such cases were 
reported in the PALOMA-1 study, whilst in the PALO-
MA-2 and PALOMA-3 studies these episodes occurred 
in eight (1.8%) and three patients (1%), respectively [32, 
33, 37]. Serious adverse events in the PALOMA-2 and 
PALOMA-3 studies occurred in 20% and 13% of pa-
tients treated in experimental arm and in 10% and 14% 
of patients receiving standard treatment, respectively. 
Non-haematological adverse events grade 3/4 reported 
in both studies in at least 1% of patients included fatigue, 
anaemia, thrombocytopaenia, and dyspnoea. In both 
studies the treatment was discontinued due to adverse 
events in the experimental and standard treatment group 
in 9.7 and 5.9% of patients, respectively, and 2.6 and 
1.7%, respectively. Thus, the addition of palbociclib to 
palliative hormone therapy in the first or further line 
has proven to be not only effective but also a safe and 
relatively well-tolerated therapeutic option.
The results of the above-mentioned PALO-
MA-3 study enabled the FDA to register the drug in 
February 2016 in combination with fulvestrant for the 
treatment of patients with HRs+/HER2– breast cancer 
after failure of prior hormone therapy.
According to the European registration of palboci-
clib, the drug can be given to both pre- and postmeno-
pausal patients in the first or subsequent treatment line. 
Registration of palbociclib in the first-line hormone 
therapy in combination with AI in premenopausal 
patients has not been directly confirmed in a phase 
3 clinical trial. In premenopausal patients, hormone 
therapy should be combined with an LHRH analogue.
Palbociclib — ongoing clinical trials  
in breast cancer patients
Although palbociclib has already been registered 
in two indications in breast cancer patients, currently 
more than 50 clinical trials of various phases are on-
going regarding its efficacy in groups of patients with 
this diagnosis [39]. In patients with advanced HRs+/ 
/HER2– breast cancer the combination of CDK 4/6 in-
hibitor with tamoxifen or fulvestrant is assessed in the 
first-line treatment. Very interesting results may be 
provided by the PEARL phase 3 study, in which patients 
after disease progression during IA treatment receive 
palbociclib combined with exemestane/fulvestrant or 
chemotherapy with capecitabine. Researchers also paid 
attention to premenopausal patients. In the FATIMA 
study the efficacy of palbociclib, exemestane, and sup-
pression of ovarian function was compared to hormone 
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therapy alone. In another study a combination of pal-
bociclib with HT was compared to chemotherapy with 
capecitabine in this group of patients. Other interesting 
studies, although phase 1b/2, assessed a combination of 
palbociclib with new drugs from the SERD group, show-
ing oral bioavailability (SAR439859 and GDC0810). 
There is also a phase 1/2 study that evaluates the efficacy 
of combination of palbociclib with hormone therapy 
(anastrozole) and anti-HER2 drugs (trastuzumab with 
pertuzumab) in first-line treatment in patients with 
advanced HRs+/HER2+ breast cancer. Patients with 
the same diagnosis are included in the phase 3 PATINA 
study, specifically patients after initial chemotherapy 
with trastuzumab and pertuzumab for maintenance 
therapy with both antibodies and hormone therapy 
with possible combination with palbociclib. Activity of 
palbociclib in HER2+ breast cancer patients with brain 
metastases is also clinically evaluated. In patients with 
advanced breast cancer with androgen receptor (AR) ex-
pression the efficacy of combination of palbociclib with 
bicalutamide is assessed. There are early stage clinical 
studies that evaluate a combination of palbociclib with 
mTOR (everolimus, AZD2014) or PI3K (gedatolisyb, 
kopanlisyb) inhibitors. Finally, palbociclib in combina-
tion with hormone therapy and optionally with immune 
checkpoint inhibitors (avelumab, pembrolizumab) was 
also evaluated in patients already being treated with 
CDK 4/6 inhibitor.
Palbociclib is also evaluated in preoperative treat-
ment in combination with hormone therapy in patients 
with HRs+/HER2– breast cancer (PELOPS, PALLET). 
Also very interesting is the design of the NEOPAL 
study, which involves patients diagnosed with luminal 
subtype of breast cancer with a small and medium risk 
assessed on the basis of PAM50 gene signature. In this 
group of patients, the efficacy of palbociclib combined 
with letrozole is compared with chemotherapy 3 × FEC 
Æ 3 × docetaxel. The PREDIXLumB study was de-
signed based on a similar idea, although the subtype 
of breast cancer was evaluated based on expression of 
ER, PgR, and Ki67. Patients with luminal B or luminal 
A subtype of breast cancer with metastatic lymph nodes 
or age under 40 years are assigned to two arms: either 
paclitaxel-based chemotherapy or hormone therapy 
combined with palbociclib. On the other hand, in the 
PREDIXLumA study the allocation to particular thera-
peutic groups depends on preliminary tumour response 
to hormone treatment (change in Ki67 expression). 
The study involved patients with luminal A subtype, 
over 40 years of age, and with the feature N0. Patients 
with good response to initial hormone therapy are 
randomised to two arms: continuation of hormone 
therapy or combination with palbociclib; in the absence 
of response patients receive combination therapy. 
There are also ongoing studies with preoperative treat-
ment in HRs+/HER2+ patients; in the PALTAM and 
NA-PHER2 studies a combination of palbociclib with 
hormone therapy and trastuzumab or double blockade 
(trastuzumab + pertuzumab) is evaluated.
The clinical value of palbociclib is also evaluated in 
an adjuvant setting. In the PALLAS study a standard 
hormone therapy alone is compared to combination with 
two-year treatment with palbociclib. The PENELOPE-B 
study is dedicated to high-risk patients who have not 
achieved pathologic complete response (pCR) after 
preoperative chemotherapy — they are assigned to 
standard hormone therapy alone or in combination with 
one-year treatment with palbociclib.
Ribociclib — pivotal studies
Preclinical studies indicate that the mechanism of 
action of ribociclib is based not only on CDK 4 and 
6 inhibition, but also on interfering with ER, PI3K, and 
HER2 signalling pathways. In addition, animal models 
have demonstrated the anti-tumour activity of ribociclib 
in melanomas with BRAF or NRAS activating mutations 
[20]. The combination of this drug with anti-estrogens 
inhibits the growth of breast tumours, whilst in combina-
tion with PI3K inhibitor it causes a dynamic regression of 
such tumours [30]. Hence, this led to premises for testing 
the combinations of these drugs in clinical trials. The 
dose of ribociclib determined in phase 1 clinical studies 
with this drug used in monotherapy [40] is 600 mg (three 
tablets); the drug is administered once daily for three 
weeks with a one week break (four-week cycle) and meal 
intake does not affect the bioavailability. The half-life of 
ribociclib is about 30 hours [41]. Ribociclib elimination 
may be impaired by cytochrome CYP3A4 inhibitors or 
activators, while the drug inhibits CYP3A4, CYP1A2, 
and BSEP with a dose-related pattern [20]. Like palboci-
clib, adverse reactions observed in early phases of clini-
cal trials were haematological disorders, but also nausea 
and fatigue, and, importantly, asymptomatic prolonga-
tion of QT interval. The MONALEESA-1 study [41] 
assessed among others pharmacodynamic parameters 
of ribociclib administered in combination with letrozole 
for 14 days prior to radical surgery in 14 postmenopau-
sal patients with early HRs+/HER2– breast cancer. 
Combination therapy compared with monotherapy with 
letrozole has been shown to have a greater effect on 
the reduction of Ki67 index in cancer cells. In addition, 
ribociclib treatment resulted in decreased expression of 
phosphorylated RB protein and decreased expression 
of CDK4, CDK6, CCND2, CCND3, and CCNE1 genes 
that are involved in the D-CDK4/6-INK4-RB cyclin 
signalling pathway.
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MONALEESA-2 study
MONALEESA-2 was a study that led to registration 
of ribociclib in breast cancer patients [42]. In this ran-
domised phase 3 study the efficacy of ribociclib combined 
with letrozole was compared with placebo with letrozole 
(dosage of ribociclib as previously described, standard 
dosage of letrozole) in first-line palliative treatment in 
postmenopausal patients with HRs+/HER2– breast 
cancer. The primary endpoint of the study was PFS as 
assessed by the investigator, and secondary endpoints 
included: OS, ORR, safety, QoL, pharmacokinetics, and 
biomarkers of response to the treatment. The study did 
not allow crossover. In total 668 patients were included; 
43% received tamoxifen for radical treatment, and 29% 
received AI [in those patients, disease-free survival 
(DFS) had to be at least 12 months]. At the time of 
preparation of the first publication median follow-up 
was 15.3 months, and patients receiving experimental 
treatment did not achieve median PFS, whilst in patients 
with standard treatment it was 14.7 months, represent-
ing a 44% reduction in risk of progression (HR 0.56; 
95% CI 0.43–0.72; p = 3.29 × 10–6 for superiority 
testing). In patients with baseline measurable disease, 
objective response rates were 53 and 37%, respectively 
(p < 0.001). Updated results of the study were presented 
at this year’s Annual ASCO Meeting (2017) [43]. At 
the time of the next analysis after more than 26 months 
of follow-up, the survival data were still insufficient, 
although a trend towards reducing the death rate was 
observed in the experimental arm (15 vs. 20%, HR 
0.75; p = 0.059). Median PFS was 25.3 and 16 months, 
respectively (HR 0.57; p = 9.63 × 10–8). Greater benefit 
of combination therapy was reported in all subgroups 
of patients: regardless of age (< 65 years, ≥ 65 years), 
race (Asian, non-Asian), PgR expression, liver or lung 
metastases, diagnosis of primary metastatic breast can-
cer, type of previous hormone therapy, or earlier use of 
chemotherapy. However, for patients with metastases 
localised only in bone, the difference in PFS was not 
statistically significant.
During this congress, the results of QoL analysis 
of patients included in the MONALEESA-2 study 
were also presented [44]. The EORTC QLQ-C30, 
QLQ-BR23, and EQ-5D-5L questionnaires were used. 
It has been shown that during treatment the QoL was 
maintained and consistent regardless of the treatment 
used. There were no statistically or clinically significant 
differences in the symptoms reported by patients such as 
fatigue, nausea, or vomiting, but the authors underlined 
the clinically important difference in the reduction of 
pain in favour of ribociclib. 
The most common adverse events grade 3/4 in ex-
perimental and standard treatment arms were neutro-
paenia (59% vs. 0.9%, respectively) and leukopaenia 
(21% vs. 0.6%, respectively). Non-haematological 
adverse events grade 3/4 were increased ALAT (9% 
vs. 1%) and ASPAT (6% vs. 1%) level, infections 
(4.2% vs. 2.4%), fatigue (2.4% vs. 1%), diarrhoea 
(1.2% vs. 0.9%), vomiting (3.6% vs. 0.9%), constipa-
tion (1.2% vs. 0%), and back pain (2.1% vs. 0.3%). 
Treatment was discontinued due to adverse events in 
7.5% and 2.1% of patients, respectively. The risk of 
neutropaenia grade ≥ 2 increased along with ribociclib 
plasma concentration. Although this was the most 
common complication of treatment with ribociclib, 
it was the reason for therapy discontinuation in less 
than 1% of patients. Febrile neutropaenia occurred 
in 1.5% of patients and was not associated with the 
need for treatment discontinuation. On the other 
hand, neutropaenia resulted in breaks in treatment 
and reduced dose of ribociclib, which allowed the in-
cidence of this complication to diminish as treatment 
progressed. A new adverse event reported in patients 
treated with ribociclib was the prolongation of QT 
interval. It was reported in 3.3 and 0.3% of patients in 
the MONALEESA-2 study, respectively. Among them, 
three patients had a break in a treatment, but only 
in one patient QT interval prolongation was a direct 
cause of treatment discontinuation [45]. These results 
indicate that the combination of ribociclib with letro-
zole is a safe therapeutic option and the side effects 
of treatment can be avoided by modifying the dosage.
The result of the MONALEESA-2 study became 
a basis for FDA registration of ribociclib in March 
2017 in combination with AI for the first-line treatment 
of postmenopausal patients with advanced HRs+/ 
/HER2– breast cancer. In August 2017 ribociclib was 
also registered in Europe.
Ribociclib — ongoing clinical trials  
in breast cancer patients
The abovementioned study was a part of the 
MONALEESA (Mammary Oncology Assessment of 
LEE011’s Efficacy and Safety) clinical trial program. It 
also includes two phase 3 studies dedicated to patients 
with advanced breast cancer. The MONALEESA-3 study 
evaluated the efficacy of ribociclib in combination with 
fulvestrant as compared to fulvestrant monotherapy in 
men and postmenopausal women with advanced HRs+/ 
/HER2– breast cancer, not previously receiving hormone 
therapy or treated with one hormone therapy line. In the 
MONALEESA-7 study a combination of ribociclib with 
tamoxifen or NSAI and goserelin was compared to hor-
mone therapy in premenopausal patients with HRs+/ 
/HER2– 1 breast cancer in the first-line of palliative 
treatment. In addition, many studies dedicated to clinical 
assessment of ribociclib in patients with different stages 
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of breast cancer are just enrolling [39]: in combination 
with hormone therapy in preoperative treatment as 
compared to chemotherapy (CORALLEEN), in adju-
vant treatment in combination with hormone, palliative 
treatment in combination with fulvestrant in patients 
previously treated with CDK 4 and 6 inhibitor and IA 
(MAINTAIN), in combination with anti-HER2 agents 
in patients with HER2+ breast cancer, in combination 
with bicalutamide in patients with so-called “triple 
negative” breast cancer with expression of androgen 
receptors, or in combination with paclitaxel in patients 
with immunohistochemically confirmed RB protein ex-
pression in tumour cells. Interestingly, several projects 
are devoted to patients with advanced cancer who have 
undergone several lines of palliative pharmacotherapy, 
including use of molecular targeted drugs such as CDK 
4 and 6 inhibitors or mTOR inhibitors. In these studies, 
ribociclib is combined with other molecular targeted 
drugs (PI3K inhibitors, mTOR inhibitors). The high 
antitumor activity of such drug combinations was 
observed in preclinical studies, as discussed above. It 
is worth mentioning two reports from the San Antonio 
Breast Cancer Symposium 2015 by Juric et al. [46] and 
Bardia et al. [47]. Only partial results from both phase 
1b/2 studies were presented. The first trial assessed 
a combination of ribociclib, the PI3K inhibitor alpelisib, 
and letrozole, and the second one a combination of ri-
bociclib, everolimus, and exemestane. In both cases, the 
researchers assessed triple therapy as active in previously 
treated breast cancer patients with acceptable toxicity 
profile and indicated the need to continue the studies 
with such combinations in subsequent phases. In addi-
tion, Bardia et al. indicate amplification of the cyclin D 
gene as a potential predictor for combination therapy 
with ribociclib and mTOR inhibitor.
Abemaciclib — pivotal studies
As mentioned above, abemaciclib is structurally 
distinct from the inhibitors discussed previously. Its 
activity against CDK 4 and 6 is 14-fold higher as 
compared to the aforementioned preparations. Abe-
maciclib also exhibits antitumor activity against HRs+/ 
/HER2+ breast cancer, non-small cell lung cancer 
(NSCLC), melanoma, glioblastoma multiforme 
(GBM), or lymphoma [29]. In addition, it crosses the 
blood-brain barrier and exhibits antitumor activity 
against cerebral metastases, which was preliminarily 
observed in animal models and confirmed in clinical 
studies [29, 48]. Serum concentration increases with 
dose, and the half-life is between 17 and 38 hours [29]. 
When used alone, the dose of abemaciclib is 200 mg 
twice daily, but in combination with hormone therapy 
the established dose is 150 mg twice daily. The drug 
is administered continuously. Abemaciclib used in 
preoperative treatment of patients with early HRs+/ 
/HER2– breast cancer, either in combination with 
AI or in monotherapy, caused a greater reduction in 
Ki67 expression as compared to AI [49].
The activity of abemaciclib in monotherapy in pa-
tients with advanced breast cancer was confirmed in the 
phase 2 MONARCH-1 study [50]. This study included 
132 patients with advanced HRs+/HER2– breast 
cancer, with documented resistance to previous hor-
mone therapy: 64% of patients received previously at 
least two lines of palliative hormone therapy. Patients 
also underwent one or two palliative chemotherapy 
regimens, and 28% of them were previously treated 
with everolimus. The median number of previous 
treatment lines was three (range 1–8). Abemaciclib 
was administered at a dose of 200 mg twice daily. The 
primary endpoint of the study was ORR, and second-
ary endpoints included, among others, the percentage 
of patients with clinical benefit (CBR), PFS, OS, and 
treatment safety. 
Objective response rate (ORR) was nearly 20%, 
clinical benefit rate was 42%, median PFS was six 
months, and median OS was almost 18 months. The 
most commonly observed grade 3/4 adverse events were: 
diarrhoea (20%), fatigue (13%), nausea (4.5%), neutro-
paenia (27%), leukopaenia (28%), thrombocytopaenia 
(2.3%), and elevated ALAT activity (1.5%). However, 
treatment was discontinued due to adverse events in less 
than 8% of patients. So, monotherapy with abemaciclib 
is a relatively safe therapeutic option for patients with 
advanced breast cancer, previously treated with multiple 
lines of palliative pharmacotherapy, and the antitumor 
activity of this drug appears to be at least as high as 
cytostatics or hormone therapies available in this indica-
tion. Based on the results of the MONARCH-1 study, 
in September 2017 FDA registered abemaciclib in 
monotherapy for the treatment of women and men with 
advanced HRs+/HER2– breast cancer with disease 
progression after previous palliative hormone therapy 
and chemotherapy. 
MONARCH-2 study
At the same time abemaciclib has also been regis-
tered in combination with fulvestrant for the treatment 
of patients with advanced HRs+/HER2– breast cancer, 
who have experienced progression after previous hor-
mone therapy. This approval was granted based on the 
phase 3 MONARCH-2 study, comparing the efficacy 
of a combination of fulvestrant with abemaciclib to ful-
vestrant monotherapy [51]. The study involved 669 pa-
tients with advanced HRs+/HER2– breast cancer, with 
disease progression during neoadjuvant or adjuvant 
hormone therapy within 12 months of completion of 
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adjuvant hormone therapy or during first-line palliative 
hormone treatment. Palliative chemotherapy was one 
of the exclusion criteria from the study. Patients were 
assigned to two study arms in a 2:1 ratio: they received 
abemaciclib (150 mg twice daily, every day) in combina-
tion with fulvestrant (standard dosage) or placebo and 
fulvestrant. The primary endpoint of the study was PFS 
as assessed by the investigator, and secondary endpoints 
included among others: OS, ORR, CBR, QoL, and 
treatment safety. In total 17% of patients included in 
the study were premenopausal; they also received a gon-
adotropin analogue. 38% of patients received previously 
one line of palliative hormone therapy, and 70% had 
previous AI. A two-drug regimen was more effective 
with respect to PFS — median was 16.4 vs. 9.3 months, 
respectively (HR 0.553; 95% CI 0.449–0.618, p = 0.001), 
ORR (48 vs. 21%, p < 0.001), and CBR (72 vs. 56%, 
p < 0.001). PFS improvement was consistently demon-
strated for all analysed subgroups (age, primary or sec-
ondary hormone resistance, PgR expression, metastatic 
location, menopausal status). At the time of publication 
preparation OS data was immature, and QoL data was not 
presented. The spectrum of adverse drug reactions in the 
MONARCH-2 study was similar to that observed in the 
abovementioned MONARCH-1 study. The most common 
grade 3/4 adverse events were diarrhoea (13% vs. 0.4%), 
neutropaenia (27% vs. 2%), nausea (2.7% vs. 1%), fatigue 
(2.7% vs. 0.4%), abdominal pain (2.5% vs. 1%), anaemia 
(7% vs. 1%), leukopaenia (9% vs. 0%), increased ALAT 
(4% vs. 2%), and ASPAT (2% vs. 3%) activity. Despite 
the high incidence of neutropaenia in patients treated with 
abemaciclib, febrile neutropaenia occurred in only four 
patients. Patients treated with experimental therapy were 
more likely to have infections, but those grade 3/4 con-
cerned 7% and 4% of the patients receiving experimental 
and standard treatment, respectively.
Diarrhoea of any intensity occurred in 86% of pa-
tients treated with abemaciclib (25% in the fulvestrant 
treated group). In patients receiving CDK 4/6 inhibitor 
diarrhoea usually appeared during the first treatment 
cycle (approximately day 6 of therapy) and resolved after 
symptomatic treatment and modification of abemaciclib 
dose, which was required in 30% of patients. In 12% of 
patients treated with inhibitor, elevated serum creatinine 
concentration (1% — in grade 3) was observed because 
the drug inhibits creatinine secretion in renal tubules.
Three deaths associated with the use of abemaciclib 
were reported in the study.
MONARCH-3 study
At the ESMO 2017 Congress the results of an-
other important study evaluating the combination of 
abemaciclib with hormone therapy in the first line of 
palliative treatment were presented. The publication 
was published shortly after presentation of study re-
sults [52]. The phase 3 MONARCH-3 study included 
493 postmenopausal patients with advanced HRs+/ 
/HER2– breast cancer, not yet receiving a palliative 
treatment. Patients were assigned to therapeutic arms 
in a 2:1 ratio — they received abemaciclib at the dose 
150 mg twice daily everyday with NSAI (anastrozole or 
letrozole) or placebo with NSAI. The primary endpoint 
of the study was PFS as assessed by the investigator, 
and secondary endpoints included, among others, 
ORR and treatment safety. The median follow-up at 
the time of analysis was 18 months. In total 40% of 
the patients included in the study were diagnosed with 
newly disseminated cancer; the remaining patients had 
disease relapse at least 12 months after completion of 
neoadjuvant or adjuvant hormone therapy. Almost 
half of the patients received prior hormone therapy 
as part of radical treatment, and 27% of patients re-
ceived AI. Almost 22% of all patients had “bone-only 
disease/metastases”. In the group of patients treated 
experimentally the PFS median was not achieved, and 
in standard treatment group it was 15 months (HR 
0.543; 95% CI 0.409–0.723, p = 0.000021). Objective 
response rate was 48% vs. 34%, respectively (p = 0.002). 
At the time of analysis, OS data was missing. Interest-
ingly, exploratory analysis has shown that a clinical 
variable, e.g. treatment-free interval (TFI), may have 
a certain predictive value for the treatment of CDK 
4 and 6 inhibitor. For patients with TFI < 36 months, 
median PFS was not achieved with abemaciclib and 
was nine months in the placebo group (HR 0.48; 95% 
CI 0.25–0.91). For patients with TFI ≥ 36 months, the 
difference in PFS was not statistically significant (HR 
0.83, 95% CI 0.46–1.52). In addition, the two-drug 
regimen was particularly beneficial in patients with 
liver metastases (HR 0.47; 95% CI 0.25–0.87). Adverse 
events reported in the MONARCH-3 study were similar 
to those observed in the abovementioned studies [52]. 
Thus, abemaciclib has joined the CDK 4 and 6 inhibitors 
group, members of which have proven to be effective 
and relatively well tolerated in the first line of pallia-
tive treatment in combination with AI in patients with 
HRs+/HER2– breast cancer.
Abemaciclib — ongoing clinical trials  
in breast cancer patients
The clinical value of abemaciclib in breast cancer 
patients is still being evaluated in numerous ongoing and 
currently recruiting clinical trials [39]. In palliative treat-
ment, the combination of abemaciclib with tamoxifen 
is compared to monotherapy with abemaciclib, and the 
combination of abemaciclib with trastuzumab ± ful-
vestrant is compared to standard chemotherapy with 
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trastuzumab in patients with HRs+/HER2+ breast 
cancer (MONARCHER); abemaciclib activity is also 
evaluated in “triple negative” breast cancer with im-
munohistochemically confirmed RB protein expression. 
Very interesting results may provide a study in which 
abemaciclib is used in patients with breast cancer, 
NSCLC and melanoma with brain metastases. The 
pharmacodynamic and clinical effects of abemaciclib 
alone or in combination with AI are evaluated in the 
neoMONARCH study, which includes patients with 
early HRs+/HER2– breast cancer. For 14 weeks prior 
to surgery patients receive abemaciclib (150 mg twice 
daily) with anastrozole, abemaciclib alone, or anastro-
zole alone. Loperamide is additionally given in primary 
prophylaxis of diarrhoea in patients treated with CDK 
4 and 6 inhibitor. The primary endpoint of the study is 
a change in Ki67 expression (these results are already 
available, and cited above), secondary endpoints 
include: treatment safety, clinical and radiological 
response, and change in gene expression associated 
with proliferation. Abemaciclib is also being studied 
in adjuvant treatment. The phase 3 MONARCH-E 
study includes patients with early breast cancer who 
are receiving standard adjuvant hormone therapy or in 
combination with abemaciclib.
Summary
Introduction of CDK 4 and 6 inhibitors to clini-
cal practice is an excellent illustration of the progress 
made in the area of cancer treatment. These drugs 
have increased the number of preparations available 
for the treatment of patients with the most common 
subtype of breast cancer in advanced stage and are an 
important advance in the prevention and reversal of 
hormone resistance. In other words, these drugs pro-
vide the opportunity for quite comfortable, effective, 
and long-lasting treatment of this incurable disease. 
Although they represent a modest progression in 
medicine, their introduction also faces serious prob-
lems, which mainly come down to limited budgets for 
the financing of antineoplastic treatment, as with many 
other medical procedures. Clinical studies published so 
far have provided a wealth of knowledge about these 
drugs; however, there are still many questions regard-
ing their practical use, which still need to be resolved. 
It is already known that these preparations, in combi-
nation with hormone therapy in patients with HRs+/ 
/HER2– receptor profiles, provide significant prolonga-
tion of PFS, regardless of whether they are used in first 
or subsequent lines. Unfortunately, there are still lacking 
data on their effects on OS, and the initial results of the 
PALOMA-1 study do not generate much enthusiasm in 
this regard. These drugs are relatively well tolerated and 
the toxicity of treatment can be controlled adequately 
by monitoring the therapy and by modifying the dose. 
Of note, the profiles of their side effects are slightly 
different. Clinical trials of CDK 4 and 6 inhibitors have 
included careful assessment of patients’ QoL, which is 
crucial during long-term hormone therapy. It is well 
known already that the use of palbociclib and ribociclib 
in the first-line of treatment does not compromise the 
QoL as compared to hormone therapy alone, and the 
addition of palbociclib to second-line treatment even 
improves it. Unfortunately, the data for abemaciclib 
have not yet been published — they are expected to be 
of interest because the drug differs slightly in dosage, 
shows a slightly different clinical effect, allows a higher 
objective response rate, and penetrates to the CNS, but 
regarding the undesirable effects, it is also character-
ised by quite a high percentage of patients affected by 
diarrhoea. An important problem associated with the 
clinical use of CDK 4 and 6 inhibitors is lack of biomark-
ers, enabling rational selection of patients who would 
benefit from therapy. For the time being it seems that 
the benefit from adding of CDK 4 and 6 inhibitors to 
first-line hormone therapy may be lesser for patients 
with long treatment-free interval (TFI ≥ 3 years). Thus, 
this new therapeutic option requires rational develop-
ment that takes into account the real needs of patients 
and financial possibilities. A summary of the most im-
portant data regarding use of CDK 4 and 6 inhibitors 
is presented in Table 1.
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Table 1. Summary of key clinical data on CDK 4 and 6 inhibitors registered for the treatment of patients with advanced 
HRs+/HER2– breast cancer
Palbociclib Ribociclib Abemaciclib
Half-life 26 hr. 30 hr. 17–38 hr.
Dosage 125 mg once daily for 3 weeks, 
followed by 1 week break
600 mg once daily for 3 weeks, 
followed by 1 week break
Monotherapy: 200 mg twice daily 
(BID) every day 
In combination with HT: 150 mg 
BID every day
Toxicity Adverse events grade 3/4:
— neutropaenia 54–65%
— leukopaenia 19–28%
— FN 1–1.8%
— fatigue 2%
Adverse events grade 3/4:
— neutropaenia 59%
— leukopaenia 21%
— increased ALAT activity 9%
— increased ASPAT activity 6% 
— FN 1.5%
— fatigue 2%
— diarrhoea 1%
grade 1/2:
— QTc prolongation 3.3%
Adverse events grade 3/4:
— diarrhea 13–20%
— neutropaenia 27%
— leukopaenia 9–28%
— nausea 3–5%
— increased ALAT activity 1.5–4%
— fatigue 1–3% 
Efficacy in 
monotherapy in 
previously treated 
patients
Study of De Michele et al. 2014
— RB+ patients
— PR 2/37
— SD 5/37
— mPFS 3.7 months
— HR+/HER2– patients
— CBR 29%
Study of Infante et al. 2014
— PR 1/18
— SD 6/18
MONARCH-1
— ORR 20%
— CBR 42%
— mPFS 6 months
— mOS 18 months
Efficacy of 
combination with 
HT in first line 
treatment
PALOMA-1, PALOMA-2
P + L vs. L
mPFS 25 vs. 14.5 months
ORR 42% vs. 35%
mOS 38 vs. 35 months, NS 
(PALOMA-1)
Comparable maintain of quality 
of life
MONALEESA-2
R+L vs. L
mPFS 25 vs. 16 months
ORR 53% vs. 37%
Comparable maintain of quality 
of life
MONARCH-3
A+L/Ana vs. L/Ana
mPFS NR vs. 15 months
ORR 48% vs. 34%
Efficacy of 
combination with 
HT in second and 
subsequent lines 
treatment
PALOMA-3
P+F vs. F
mPFS 11 vs. 5 months
ORR 10% vs. 6%
Longer maintain of quality of life
MONALEESA-3
Ongoing
MONARCH-2
A+F vs. F
mPFS 16 vs. 9 months
ORR 48% vs. 21%
CBR 72% vs. 56%
Negative 
predictive factors
No For first line — bone-only 
metastases1
For first line — bone-only 
metastases1, TFI ≥ 36 months
Registration 
status
Registered by FDA and EMA in 
combination with HT in first as well 
as second and subsequent lines
Registered by FDA and EMA in 
combination with HT in first line
Registered by FDA in monotherapy 
and in combination with HT in 
second and subsequent lines
1Characteristics “bone-only metastases” has a dubious predictive value for first line treatment with CDK inhibitors 4 and 6 for the following reasons: contrary 
results have been obtained for particular drugs — in the PALOMA-2 study this feature was related to greater benefit from combination treatment — HR 
0.36 (0.22–0.59); in MONALEESA-2 and MONARCH-3 studies HR values are threshold; in the individual studies there is no uniform definition of the concept 
“bone only disease/metastases” and assessment of bone metastases progression is not precise
FN — febrile neutropaenia; QTc — Corrected QT Interval; RB+ — immunohistochemically confirmed expression of RB protein; PR — partial response; SD — stable 
disease; ORR — overall response rate; CBR — clinical benefit rate; mPFS — median progression-free survival; mOS — median overall survival; P — palbociclib; 
L — letrozole; R — ribociclib; A — abemaciclib; F — fulvestrant; Ana — anastrozole; HT — hormone therapy; TFI — treatment-free interval; FDA — Food and 
Drug Administration; EMA — European Medicines Agency; NS — not significant; NR — not reached
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